A lot of things could have caused the price to jump today.

New Post Public Reply Private Reply Replies (1) Message Board
joey68 Pugilista #238
A lot of things could have caused the price to jump today. talking about share price actually has nothing to do with what the company is worth.

Quote:

That being said, the principal theory is that the price movement of a stock indicates what investors feel a company is worth. Don't equate a company's value with the stock price. The value of a company is its market capitalization, which is the stock price multiplied by the number of shares outstanding. For example, a company that trades at $100 per share and has 1 million shares outstanding has a lesser value than a company that trades at $50 that has 5 million shares outstanding ($100 x 1 million = $100 million while $50 x 5 million = $250 million). To further complicate things, the price of a stock doesn't only reflect a company's current value, it also reflects the growth that investors expect in the future.


http://www.investopedia.com/university/stocks/stocks4.asp

I believe the quote below sums it up:

Quote:
it is investors' sentiments, attitudes and expectations that ultimately affect stock prices.


SCIE, in my opinion is grossly undervalued . Several weeks ago I posted about another company (LOG$) which has no product, never had a product, and probably never will; yet their PPS went to 30 CENTS only two weeks ago. Its insane!

Could you image how rich we'd be if SCIE was at .30 cents right now?? And SCIE HAS a product! I think investor sentiment is on the rise; finally beginning to see SCIE for what it is - a real company, with a real CEO, with a real product that actually works. If SCIE had continual sales, what would honestly be keeping them from reaching .50 cents? Nothing in my opinion.

My personal opinion as to what happened today? Insider trading. GASP! no, not the bad illegal kind; theres actually a legal side to insider trading which many people tend to forget about or ignore because its not dramatic enough to talk about in posts.

This sums it up:
http://www.investopedia.com/articles/02/061202.asp

For new investors, its a a good read.

This is a great sentence:

Quote:
The SEC considers insiders to be company directors, officials or any individual with a stake of 10% or more in the company. Insiders are required to report their insider transactions within two business days of the date the transaction occurred (before the 2002 Sarbanes-Oxley Act it used to be the 10th day of the following month). For example, if an insider sold 10,000 shares on Monday, June 12, he or she would have to report this change by Wednesday, June 14. Changes in insider holdings are sent to the SEC electronically as a Form 4, which details a company's insider trades or loans. The following link is an example of a Form 4 filed by the CEO of Krispy Kreme Doughnuts. A Form 14a, also filed by the company, lists all the directors and officers along with the share interest they have.


Of course, this may not be the case with SCIE. Perhaps no insider trading occurred (the legal kind). But if it did, guess what? If it did, we would see a SEC filing this Friday at the earliest. And if that happens, it would be great for us. If it doesn't happen, that's fine too; it simply means this post doesn't relate to SCIE this time. Of course, with the SEC, there are always exceptions to the rules, so don't go crying if/when no SEC filing doesn't show up by Friday.

An even better sentence...

Quote:
This kind of information is extremely valuable to individual investors. For example, if insiders are buying shares in their own companies, they usually know something that normal investors do not. They might buy because they see great potential, a merger, acquisition or simply because they think their stock is undervalued.

So, if someone inside SCIE knows something we don't about the recent oncoscope merger... the spike in PPS might be related to that as well.


This post might be completely wrong about todays price action, but it does give reason as to why price change may occur. Time will tell.

SpectraSCIENCE Inc. (SCIE) Stock Research Links

SCIE Board Company Profile Buy Rating Time & Sales News Filings Financials
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 94

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 111

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 105

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Surgery Partners Deal Faces Fresh Price Scrutiny Ahead

Updated Category News Views 66

A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 23

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
Bybit Adds ANT, but Trading Access Has Real Fine Print

Updated Category News Views 50

Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 47

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading

Top 5 Most Recently Viewed Articles

Deere & Co's Future Amid Repair Debates and Financial Insights

Updated Category News Views 81

Barclays Reconfirms Target for Deere & Co Barclays recently reaffirmed its Overweight rating on Deere & Co (NYSE: DE) and maintained a $400 price target, amidst an ongoing dialogue surrounding the right to repair. This discussion has re-emerged in the spotlight, temporarily impacting Deere's share price before it regained ground. The analyst noted that this issue has been...

Continue Reading
Inventor Offers Hospital Sign to Prevent Infections

Updated Category News Views 38

A Fresh Take on Infection Control Some days you stumble across an idea that just clicks—like the latest gadget for hospitals. Forget complex systems or high-tech cameras; this is about a simple sign that screams 'stop!' before you walk into trouble. It’s designed to safeguard hospital staff by alerting them to take precautions before entering rooms with infectious...

Continue Reading
JPMorgan Adjusts NOV Stock Outlook Amidst Market Challenges

Updated Category News Views 64

JPMorgan Adjusts NOV Stock Outlook Recently, JPMorgan made changes to its financial outlook for NOV Inc. (NYSE: NOV), a key player in the energy equipment and services sector. The investment firm lowered its price target from $23 to $22 but maintained an Overweight rating on the stock. This adjustment was driven by expectations of a slowdown in North American operations...

Continue Reading
Madrigal Pharmaceuticals Expands Workforce with Incentive Awards

Updated Category News Views 234

Madrigal Pharmaceuticals Strengthens Workforce with New Grants Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a leading biopharmaceutical company dedicated to innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), has recently taken a significant step to bolster its team. The company announced granting equity inducement awards to 76 new...

Continue Reading
Pomerantz Investigates Investor Claims Against Abacus Global Management

Updated Category News Views 272

Pomerantz Law Firm's Investigation into Abacus Global Management In recent news, the Pomerantz Law Firm has embarked on an investigation regarding Abacus Global Management, Inc. (NASDAQ: ABL). This investigation revolves around potential securities fraud and other unlawful business practices committed by the company and some of its executive members. For investors...

Continue Reading